Organization
Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China
1 abstract
Abstract
Neoadjuvant docetaxel-cisplatin followed by concurrent chemoradiotherapy and adjuvant tislelizumab for locally advanced nasopharyngeal carcinoma: A multicenter, single-arm, phase II trial.Org: Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China, Guangzhou Medical University Cancer Center, Guangzhou, China, Department of Radiation Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China, Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China, Department of Radiation Oncology, The Central Hospital of Shaoyang, Shaoyang, Hunan, China,